Table 1.
Report of CRP transgenic pig heart and kidney transplantation into primates, and comparison with Gal-KO. In addition, the best record for reference.
| I. Heart (Hetero) | ||||
|---|---|---|---|---|
| Pigs | Recipient | Survival days | Immunosuppression | Report |
| CD46 | Baboon | 1h – 16 (5.25) | none | Adams et al. (38) |
| CD46 | Baboon | 15 – 137 (96) | Rituximab, ATG, TPC, FK506, Rapa, CS | McGregor et al. (39) |
| CD55 | Baboon | (5.1) | none | Thompson (40) |
| CD55 | Baboon | 4 – 139 (27) | GAS914, ATG, sCR1, LoCD2b, Thymic irradiation, MMF, CVF, anti-CD154, CS |
Houser et al. (41) |
| CD59 | Baboon | 2.25 – 3.0 h. | none | Diamond et al. (42) |
| Gal-KO | Baboon | 16 – 179 (78) | ATG, LoCD2b, Thymic irradiation, CVF, anti-CD154, MMF, CS | Kuwaki et al. (43) |
| Gal-KO with CD46 and TBM | Baboon | Max 2.5 years | Anti-CD20, ATG, anti-CD40, CVF, CS | Muhiuddin et al. (44) |
| II. Heart (Ortho) | ||||
| Pigs | Recipient | Survival days | Immunosuppression | Report |
| CD46 | Baboon | 34 - 57 (40) | αGal-polymer, anti-CD20, ATG, FK506, Rapa, CS | McGregor et al. (45) |
| CD55 | Baboon | 39 | CyP, CsA, MMF, CS | Vial (46) |
| Gal/β4GalNT2/GHR-KO with CD46, TBM, EPCR and CD47 | Baboon | 182, 264 | Anti-CD20, ATG, anti-CD40, CVF, CS | Muhiuddin* |
| III. Kidney | ||||
| Pigs | Recipient | Survival days | Immunosuppression | Report |
| CD46 | Baboon | 13 – 15 (14) | CsA, CyP, CS, splenectomy, affinity colum for anti-Gal Ab | Dean et al. (47) |
| CD55 | Cynomolgus | 5 – 78 (35) | CsA, CyP, CS, splenectomy | Cozzi et al. (48) |
| CD55 | Baboon | 21 – 36 (23) | GAS914, CyP, ATG, CsA, Rapa, CS | Ghanekar et al. (49) |
| Gal-KO | Baboon | 20 – 34 (29) | ATG, LoCD2b, CVF, anti-CD154, MMF, CS | Yamada et al. (50) |
| Gal-KO with CD55 | Rhesus | >70 – 499 (328) | anti-CD4mAb, anti-Cd154mAb, MMF, CS | Kim et al. (51) |
ATG, anti-thymocyte globulin; TPC, anti-Gal-polyethyleneglycol conjugate; Rapa, rapamycin; CS, steroid; GAS914, a soluble Gal (α1-3) Gal polymer; CVF, cobra venom factor; LoCD2b, rat anti-primate CD2b monoclonal antibody; sCR1, soluble complement receptor type I;
MMF, mycophenolate mofetil; CsA, cyclosporine; CyP, cyclophosphamide.
* : Mohiuddin MM, 215.4 Select Life-Supporting Multi-Gene Cardiac Xenografts from Swine Demonstrate Survival >8 months in Baboons, with implications for human Clinical Trials. The Joint Congress of the International Xenotransplantation Association (IXA) and the Cell Transplant and Regenerative Medicine Society (CTRMS), taking place virtually. September 23-25, 2021.